Guillain-Barré Syndrome Managed with IVIG Therapy
Quick Summary — What This Case Is About
| Condition | Guillain-Barré Syndrome (GBS) — Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) |
| Procedure | Intravenous Immunoglobulin (IVIG) Therapy — 5-day infusion protocol |
| Surgeon | Dr. Guruprasad Hosurkar | KIMS Hospital, Mahadevapura | Bangalore |
| Technique | IVIG 0.4 g/kg/day for 5 consecutive days · Inpatient monitoring · Supportive respiratory and autonomic care |
| Outcome | Complete neurological recovery with return of independent mobility |
| Complications | None reported |
Patient identity has been withheld throughout this case study in line with confidentiality guidelines. No name, photograph, or identifying detail is included.
PATIENT PROFILE
| Age | 34 years |
| Gender | Male |
| Occupation | Software Professional |
| City | Bangalore |
| Presenting Complaint | Rapidly progressive weakness beginning in both legs and ascending toward the arms, accompanied by tingling in the hands and feet |
| Diagnosis | Guillain-Barré Syndrome, AIDP variant, confirmed on nerve conduction study and cerebrospinal fluid analysis showing albuminocytological dissociation |
| Duration of Issue | Symptoms progressed rapidly over 4 days before hospital admission |
| Previous Treatments | None — patient presented directly to the KIMS Hospital emergency department as symptoms worsened |
| Date of Procedure | June 2026 |
| Outcome | Excellent — full motor recovery |
Patient identity withheld per confidentiality guidelines. All other fields reflect the case accurately.
THE PROBLEM
Condition
The patient developed Guillain-Barré Syndrome, an autoimmune condition in which the body’s immune system mistakenly attacks the peripheral nerves. Weakness began in both legs and climbed upward over a matter of days, a pattern typical of the ascending paralysis seen in this condition. By the time of admission, the patient was struggling to stand unsupported and reported numbness spreading through the hands and feet. There was no clear single trigger, though a mild febrile illness in the preceding two weeks was reported, consistent with the post-infectious onset commonly seen in GBS.
Emotional & Psychological Impact
The speed of the decline was frightening for both the patient and the family. Within days, a person who had been walking to work independently could no longer climb stairs without support. There was considerable anxiety about whether the weakness would keep spreading, particularly toward the chest and breathing muscles, and about how long recovery might take. The uncertainty around an unfamiliar diagnosis added to the distress, and the family needed clear, repeated reassurance about the treatment plan and expected recovery trajectory before they felt settled.
CONSULTATION & TREATMENT PLAN
What Was Assessed During the Consultation?
- Detailed neurological examination — muscle power grading (MRC scale), deep tendon reflexes, and sensory testing across all limbs
- Nerve conduction studies to confirm demyelinating polyradiculoneuropathy
- Cerebrospinal fluid analysis for albuminocytological dissociation, a hallmark of GBS
- Respiratory function monitoring, including forced vital capacity, given the risk of ascending involvement of breathing muscles
- Screening for autonomic instability — heart rate and blood pressure fluctuations
- Swallowing assessment to rule out bulbar involvement
Why IVIG Therapy Was Chosen
Dr. Guruprasad Hosurkar, a leading neurologist in Bangalore specializing in autoimmune and inflammatory neurological conditions, recommended Intravenous Immunoglobulin therapy as first-line treatment. His clinical reasoning included:
- IVIG could be started immediately through a standard IV line, without waiting for a dedicated apheresis unit
- Evidence supports comparable efficacy between IVIG and plasma exchange in AIDP, with a more favourable side-effect profile for this patient’s clinical picture
- Stable hemodynamics made IVIG the safer option, avoiding the blood pressure swings sometimes associated with plasmapheresis
- Early administration, within the first week of symptom onset, offered the best chance of halting disease progression
According to Dr. Guruprasad Hosurkar, “Guillain-Barré Syndrome can progress within hours, so the priority is always to assess respiratory reserve and start immunotherapy without delay. Early IVIG changes the entire trajectory of recovery.” More on the condition and its management is covered on our Guillain-Barré Syndrome Treatment page.
BASELINE CLINICAL ASSESSMENT
As GBS is managed medically rather than surgically, baseline documentation consisted of a detailed neurological grading chart rather than clinical photographs. Power was graded at 2/5 in the lower limbs and 4/5 in the upper limbs on admission, with absent ankle and knee reflexes bilaterally — findings that were tracked serially through the course of treatment to confirm response to therapy.
TREATMENT DETAILS
Step-by-Step Overview
- Admission with a detailed neurological and respiratory baseline assessment
- Intravenous line secured and confirmed for infusion access
- IVIG infusion commenced at 0.4 g/kg/day, with the infusion rate titrated gradually to monitor tolerance
- Continuous monitoring of vital signs, oxygen saturation, and forced vital capacity every 6 hours
- Daily neurological reassessment of muscle power and reflexes to track response
- Physiotherapy introduced early in the course to preserve joint mobility and prevent deconditioning
- Autonomic parameters (heart rate, blood pressure) monitored closely through the 5-day course
- IVIG completed over 5 consecutive days, reaching a cumulative dose of 2 g/kg
Treatment Facts
| Duration | 5-day inpatient IVIG infusion course |
| Setting | High-dependency monitoring for the first 48–72 hours, stepped down to the general ward as stability was confirmed |
| Dose | IVIG 0.4 g/kg/day for 5 days (cumulative 2 g/kg) |
| Route | Peripheral intravenous infusion |
| Treatment-Related Complications | None |
| Hospital Stay | Approximately 10–12 days, including the IVIG course and recovery monitoring |
POST-TREATMENT RESULTS
The patient responded well to IVIG therapy, with steady improvement in limb power noted from day 4 of the infusion onward. By the time of discharge, the patient could stand and walk short distances with minimal support, a marked change from the near-total lower limb weakness seen on admission. Sensory symptoms in the hands and feet also resolved gradually over the following weeks.
Outcomes at a Glance
| Motor Recovery | ✔ Excellent — power improved from 2/5 to 5/5 in the lower limbs by 3-month follow-up |
| Respiratory Status | ✔ Stable throughout — no ventilatory support required |
| Patient Satisfaction | ✔ Very high — patient reported renewed confidence in day-to-day mobility |
| Complications | ✔ None |
| Recovery | ✔ Smooth, within the expected timeline for AIDP managed with early IVIG |
PATIENT FEEDBACK
Google Review ★★★★★ 5.0 — Verified Patient (Name withheld for privacy)
“I couldn’t stand on my own for almost a week, and I remember being scared it would keep getting worse. Once the IVIG treatment started, I could feel small improvements every day. By the time I was discharged, I was walking again, and that felt like getting my life back.”
Profile: Male · 34 years · Software Professional · Bangalore
Treatment: IVIG Therapy for Guillain-Barré Syndrome · KIMS Hospital, Mahadevapura, Bangalore · June 2026
Neurologist: Dr. Guruprasad Hosurkar
POST TREATMENT CARE & RECOVERY
Instructions Given to Patient
- Structured physiotherapy focusing on limb strengthening and gait training
- Breathing exercises to support respiratory muscle recovery
- Follow-up nerve conduction study scheduled at 6 weeks to confirm nerve healing
- Vitamin B-complex supplementation as supportive nutritional care
- Gradual, monitored return to daily activities and work, avoiding overexertion in the early weeks
- Clear guidance on relapse warning signs (renewed weakness, breathing difficulty) with instructions to seek immediate review
Recovery Timeline
| Day 1–5 | IVIG infusion course, closely monitored on the ward for respiratory and autonomic stability |
| Week 1–2 | Physiotherapy initiated at the bedside; standing and assisted walking begin |
| Week 4–6 | Independent walking without support; follow-up nerve conduction study performed |
| Month 3 | Near-normal limb strength; return to regular work activities |
| Month 6 | Full neurological recovery confirmed at follow-up review |
Disclaimer:
This case study is for educational purposes only and does not replace professional medical advice. Patient identity has been withheld throughout in line with confidentiality guidelines.